<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04091945</url>
  </required_header>
  <id_info>
    <org_study_id>LT3001-201</org_study_id>
    <nct_id>NCT04091945</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS</brief_title>
  <official_title>A Phase IIa, Double-Blind, Single Dose, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Potential Efficacy of LT3001 Drug Product in Subjects With Acute Ischemic Stroke (AIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lumosa Therapeutics Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lumosa Therapeutics Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, double-blind, single-dose, randomized, and placebo-controlled
      prospective Phase IIa clinical study, designed to evaluate LT3001 drug product versus
      placebo/control in subjects with AIS.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety of a single dose LT3001 drug product in subjects with AIS</measure>
    <time_frame>36 hours</time_frame>
    <description>The occurrence of symptomatic intracranial hemorrhage (sICH)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>LT3001 Drug Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LT3001 Drug Product</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>LT3001 Drug Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 90 years

          -  NIHSS of 4 to 30

          -  Diagnosis of AIS within 24 hours after stroke symptoms onset

        Exclusion Criteria:

          -  Treatement with approved drug during the current AIS

          -  Pre-stroke disability

          -  Imaging evidence of acute intracranial hemorrhage, intraparenchymal tumor,
             arteriovenous malformations, other central nervous system lesions that could increase
             bleeding risk, or aneurysm requiring treatment

          -  Suspected subarachnoid hemorrhage

          -  Seizure

          -  Uncontrolled hypertension

          -  INR &gt;1.7 and/or abnormal aPTT or platelet count &lt;100,000/mm3

          -  Blood glucose concentration &lt;50 mg/dL or &gt;400 mg/dL

          -  Lactating or pregnant subjects or those planning to become pregnant during the study

          -  Received anticoagulants and/or antiplatelet therapy and glycoprotein IIb/IIIa
             inhibitors within 48 hours

          -  AIS, myocardial infarction, serious head trauma or major surgery within 90 days

          -  Bleeding event within 21 days

          -  Puncture of noncompressible vessels within 7 days

          -  Severe hepatic, renal, and/or infectious disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>September 13, 2019</last_update_submitted>
  <last_update_submitted_qc>September 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

